Teva Makes Right Choice, Baidu Looks Weak, Yelp Gets Own Review

In Tuesday’s Analysts' Actions, Wall Street firms review Teva Pharmaceutical Industries (TEVA), Baidu (BIDU), and Yelp (YELP).
Author:
Publish date:

In Tuesday’s Analysts' Actions, Wall Street firms review Teva Pharmaceutical Industries (TEVA), Baidu (BIDU), and Yelp (YELP). Analysts at BMO Capital Markets upgraded shares of Teva to OUTPERFORM from MARKET PERFORM with a higher $80 price target. The firm likes its deal to buy Allergan's (AGN) generics business for $40.5 billion and dropped its proposal to acquire Mylan (MYL). Analysts at Brean Capital lowered their rating on Baidu to HOLD from BUY, saying they see muted earnings growth as the Chinese Internet search provider makes its O2O, or online to offline, transition. And, analysts at Deutsche Bank downgraded Yelp to HOLD from BUY with a $33 price target, citing problems with its salesforce. The firm noted that its confidence in Yelp’s business and strategic value is fading. TheStreet's Kurumi Fukushima reports in New York.